EXPEDITED PUBLICATION: VIEWPOINT
Thinking Outside the "Box"—The Ultrasound Contrast Controversy
Michael L. Main, MD, FACC*,1,*,
Jonathan H. Goldman, MD, FACC ,2 and
Paul A. Grayburn, MD, FACC ,3
* Mid America Heart Institute, Kansas City, Missouri
University of California San Francisco, San Francisco, California
Baylor University Medical Center, Dallas, Texas.
Manuscript received November 5, 2007;
revised manuscript received November 12, 2007,
accepted November 13, 2007.
* Reprint requests and correspondence: Dr. Michael L. Main, Cardiovascular Consultants, 4330 Wornall Road, Suite 2000, Kansas City, Missouri 64111. (Email: mmain{at}cc-pc.com).
On October 10, 2007, the U.S. Food and Drug Administration (FDA) announced a new "black box" warning for the perflutren-containing ultrasound contrast agents, contraindicating their use in patients with acute coronary syndromes, acute myocardial infarction, and worsening or clinically unstable heart failure. These warnings ignore the proven efficacy of ultrasound contrast agents, the previously established safety of these compounds, the potential risks of alternative procedures, and the likely confounding effect of pseudocomplication. We suggest that the FDA Medical Imaging Division convene a panel of cardiologists experienced in a variety of imaging modalities to fully assess the adverse events that have been attributed to these agents and that any future FDA warnings acknowledge the possible influence of pseudocomplication, the proven efficacy of the modality in question for early and accurate diagnosis of cardiovascular disease, and the known and theoretical risks of alternative testing that may be necessary.
|
Abbreviations and Acronyms
| | FDA = Food and Drug Administration | | LV = left ventricular |
|
This article has been cited by other articles:
|
|
|
|
 
S A Mollema, G Nucifora, and J J Bax
Prognostic value of echocardiography after acute myocardial infarction
Heart,
November 1, 2009;
95(21):
1732 - 1745.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Main
Ultrasound Contrast Agent Safety: From Anecdote to Evidence
J. Am. Coll. Cardiol. Img.,
September 1, 2009;
2(9):
1057 - 1059.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. T. Laing and D. D. McPherson
Cardiovascular therapeutic uses of targeted ultrasound contrast agents
Cardiovasc Res,
September 1, 2009;
83(4):
626 - 635.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Weinsaft, R. J. Kim, M. Ross, D. Krauser, S. Manoushagian, T. M. LaBounty, M. D. Cham, J. K. Min, K. Healy, Y. Wang, et al.
Contrast-Enhanced Anatomic Imaging as Compared to Contrast-Enhanced Tissue Characterization for Detection of Left Ventricular Thrombus
J. Am. Coll. Cardiol. Img.,
August 1, 2009;
2(8):
969 - 979.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Wilson, L. D. Greenbaum, and B. B. Goldberg
Contrast-Enhanced Ultrasound: What Is the Evidence and What Are the Obstacles?
Am. J. Roentgenol.,
July 1, 2009;
193(1):
55 - 60.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ionescu
Bubble trouble: anaphylactic shock, threatened myocardial infarction, and transient renal failure after intravenous echo contrast for left ventricular cavity opacification preceding dobutamine stress echo
Eur J Echocardiogr,
July 1, 2009;
10(5):
707 - 710.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. M. Asch and N. J. Weissman
Overview of the 2008 Food and Drug Administration Advisory Committee on Safety Considerations in the Development of Ultrasound Contrast Agents
Circulation,
April 14, 2009;
119(14):
1956 - 1961.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Senior, M. Monaghan, M. L. Main, J. L. Zamorano, K. Tiemann, L. Agati, N. J. Weissman, A. L. Klein, T. H. Marwick, M. Ahmad, et al.
Detection of coronary artery disease with perfusion stress echocardiography using a novel ultrasound imaging agent: two Phase 3 international trials in comparison with radionuclide perfusion imaging
Eur J Echocardiogr,
January 1, 2009;
10(1):
26 - 35.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. H Marwick
How dangerous is echocardiographic contrast?
Heart,
December 1, 2008;
94(12):
1522 - 1523.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Nucifora, N. A. Marsan, H.-M. J. Siebelink, J. M. van Werkhoven, J. D. Schuijf, M. J. Schalij, D. Poldermans, E. R. Holman, and J. J. Bax
Safety of contrast-enhanced echocardiography within 24 h after acute myocardial infarction
Eur J Echocardiogr,
November 1, 2008;
9(6):
816 - 818.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Adler, S. Fealy, J. R. Rudzki, W. Kadrmas, N. N. Verma, A. Pearle, S. Lyman, and R. F. Warren
Rotator Cuff in Asymptomatic Volunteers: Contrast-enhanced US Depiction of Intratendinous and Peritendinous Vascularity
Radiology,
September 1, 2008;
248(3):
954 - 961.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Vorobiof
Do Conflicts of Interest Really Matter or Does No One Read the Fine Print Anyway?
J. Am. Coll. Cardiol.,
May 13, 2008;
51(19):
1911 - 1911.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Main, J. H. Goldman, and P. A. Grayburn
Reply
J. Am. Coll. Cardiol.,
May 13, 2008;
51(19):
1911 - 1911.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Herzog
Incidence of Adverse Events Associated With Use of Perflutren Contrast Agents for Echocardiography
JAMA,
May 7, 2008;
299(17):
2023 - 2025.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. L. Kusnetzky, A. Khalid, T. M. Khumri, T. G. Moe, P. G. Jones, and M. L. Main
Acute Mortality in Hospitalized Patients Undergoing Echocardiography With and Without an Ultrasound Contrast Agent: Results in 18,671 Consecutive Studies
J. Am. Coll. Cardiol.,
April 29, 2008;
51(17):
1704 - 1706.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
